Lee-Anne Zinetti, Executive Director, Precision Medicine Strategy – Oncology Portfolio at Novartis shared a post by Adrian Charbin, Executive Director, Solid Tumor Strategy at Novartis, on LinkedIn, adding:
“Exciting progress in biomarker-driven oncology!
Targeting PI3K pathway alterations, present in a substantial proportion of patients, reinforces the importance of identifying the right patients, improving outcomes, and enabling more efficient clinical development.
A meaningful step forward for precision medicine and continued progress toward more selective therapies for patients who need them most.
Congratulations to the teams involved at both Novartis and Synovation.”
Quoting Adrian Charbin‘s post:
“Happy to share this news today. PIK3CA mutations occur in ~40% of HR+HER2- breast cancer patients (as well as in many other cancers). We are excited about the potential of SNV4818 to address the needs of these patients and it was a pleasure to work alongside Charles Larue to make the case for this deal.
A big congratulations to the Novartis team, as well as to Synovation for building a great molecule!”
Other articles about Breast Cancer on OncoDaily.